Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 0870 • ACR Convergence 2020
Hydroxychloroquine Is Associated with Lower Platelet Activity and Improved Vascular Health in Systemic Lupus Erythematosus
Michael Golpanian¹, Elliot Luttrell-Williams², MacIntosh Cornwell², Khrystyna Myndzar², Hanane El Bannoudi², Ashira Blazer², Stuart Katz², Nathaniel Smilowitz², Kelly Ruggles², Robert Clancy³, Jill Buyon⁴ and Jeffrey Berger², ¹New York University, New York, NY, ²New York University School of Medicine, New York, ³NYU School of Medicine, New York, ⁴Department of Medicine, NYU School of Medicine, New York, NY
Background/Purpose: Patients with systemic lupus erythematosus (SLE) are at increased risk of premature atherosclerosis and thrombosis. Hydroxychloroquine (HCQ) is widely used in the treatment of…
Abstract Number: 0986 • ACR Convergence 2020
BIIB059, a Humanized Monoclonal Antibody Targeting Blood Dendritic Cell Antigen 2 on Plasmacytoid Dendritic Cells, Shows Dose-Related Efficacy in a Phase 2 Study in Participants with Active Cutaneous Lupus Erythematosus
Victoria Werth¹, Richard Furie², Juanita Romero-Díaz³, Sandra Navarra⁴, Kenneth Kalunian⁵, Ronald van Vollenhoven⁶, Filippa Nyberg⁷, Benjamin Kaffenberger⁸, Saira Sheikh⁹, Goran Radunovic¹⁰, Xiaobi Huang¹¹, Hua Carroll¹², Francois Gaudreault¹², Adam Meyers¹¹, Catherine Barbey¹³, Cristina Musselli¹¹ and Nathalie Franchimont¹¹, ¹University of Pennsylvania and the Michael J. Crescenz VA Medical Center, Philadelphia, PA, ²Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY, ³Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico, ⁴University of Santo Tomas, Manila, Philippines, ⁵University of California San Diego, La Jolla, CA, ⁶Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, Amsterdam, Netherlands, ⁷Karolinska University Hospital, Stockholm, Sweden, ⁸Ohio State University, Columbus, OH, ⁹Division of Rheumatology, Allergy and Immunology, University of North Carolina, Chapel Hill, NC, ¹⁰Institute of Rheumatology, University of Belgrade, Belgrade, Serbia, ¹¹Biogen, Cambridge, MA, ¹²Biogen, Cambridge, ¹³Biogen, Baar, Switzerland
Background/Purpose: No approved targeted therapies have been developed for cutaneous lupus erythematosus (CLE), a disfiguring autoimmune disease that severely impairs quality of life.1 BIIB059 is…
Abstract Number: 1131 • ACR Convergence 2020
Patient Perspective of Helpfulness of Lupus Medications: A Qualitative Study of Medication Use Within the Type 1 and 2 SLE Model
Mithu Maheswaranathan¹, Kevin McKenna², Amy Corneli², David Pisetsky³, Megan Clowse⁴ and Amanda Eudy¹, ¹Duke University, Durham, NC, ²Duke University, Durham, ³Duke University Medical Center, Durham, NC, ⁴Duke University, Chapel Hill, NC
Background/Purpose: Medication management in systemic lupus erythematosus (SLE) is particularly complex given the clinical heterogeneity of symptoms and a wide range of medications used. We…
Abstract Number: 1268 • ACR Convergence 2020
Structural Validity of a Comprehensive Neuropsychological Battery for Assessment of Cognitive Impairment in Systemic Lupus Erythematosus: Exploratory Factor Analysis Confirms Six Cognitive Domains
Bahar Moghaddam¹, Robin Green², Dorcas Beaton³, Kathleen Bingham⁴, Mahta Kakvan⁵, Lesley Ruttan², Carmela Tartaglia⁶, Marvin Fritzler⁷, May Choi⁸, Jiandong Su⁵, Juan Pablo Diaz-Martinez⁵, Dennisse Bonilla⁵, Nicole Anderson⁵, Joan Wither⁵, Patricia Katz⁹ and Zahi Touma¹, ¹University of Toronto, toronto, ON, Canada, ²Toronto Rehabilitation Institute, University Health Network, Toronto, ON, Canada, ³Institute for Work & Health, Toronto, ON, Canada, ⁴Department of Psychiatry, University of Toronto, Toronto, ON, Canada, ⁵University of Toronto Lupus Clinic, Centre for Prognosis Studies in Rheumatic Diseases, Toronto Western Hospital, University Health Network, Toronto, ON, Canada, ⁶University of Toronto, Krembil Neurosciences Centre, Toronto, ON, Canada, ⁷Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ⁸Brigham and Women's Hospital | Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ⁹University of California, San Francisco, Novato, CA
Background/Purpose: Systemic Lupus Erythematosus (SLE) can lead to neuropsychiatric manifestations including cognitive impairment (CI). The gold standard for assessment of SLE cognitive function is the…
Abstract Number: 1284 • ACR Convergence 2020
Application of a Novel Method for Determination of Muscle Mass Relative to Fat Mass in Women with Systemic Lupus Erythematosus and Association with Disability
Sarah Lieber¹, Patricia Katz², Joshua Baker³, Deanna Jannat-Khah⁴, Dina Sheira¹ and Lisa Mandl¹, ¹Hospital for Special Surgery, New York, NY, ²University of California, San Francisco, Novato, CA, ³University of Pennsylvania, Philadelphia, PA, ⁴Hospital for Special Surgery, New York City, NY
Background/Purpose: Patients with SLE are at risk for both skeletal muscle loss and increased adiposity, which may predispose to worse health-related quality of life. Decreased…
Abstract Number: 1300 • ACR Convergence 2020
Identifying Cognitive Impairment in Patients with Systemic Lupus Erythematosus Using Hidden Markov Models: A Bayesian Approach
Juan Pablo Diaz-Martinez¹, Kathleen Bingham², Robin Green³, Dorcas Beaton⁴, Mahta Kakvan¹, Lesley Ruttan³, Carmela Tartaglia⁵, Marvin Fritzler⁶, May Choi⁷, Jiandong Su¹, Dennisse Bonilla¹, Nicole Anderson¹, Joan Wither¹, Patricia Katz⁸ and Zahi Touma⁹, ¹University of Toronto Lupus Clinic, Centre for Prognosis Studies in Rheumatic Diseases, Toronto Western Hospital, University Health Network, Toronto, ON, Canada, ²Department of Psychiatry, University of Toronto, Toronto, ON, Canada, ³Toronto Rehabilitation Institute, University Health Network, Toronto, ON, Canada, ⁴Institute for Work & Health, Toronto, Canada, ⁵University of Toronto, Krembil Neurosciences Centre, Toronto, ON, Canada, ⁶Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ⁷Brigham and Women's Hospital | Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ⁸University of California, San Francisco, Novato, CA, ⁹University of Toronto Lupus Clinic, Centre for Prognosis Studies in Rheumatic Diseases, Toronto Western Hospital, University Health Network; Krembil Research Institute, Toronto, ON, Canada
Background/Purpose: Cognitive impairment (CI) is usually operationalized on the American College of Rheumatology Neuropsychological Battery (ACR-NB) as a z-score of ≤-1.5 on ≥2 domains or…
Abstract Number: 1510 • ACR Convergence 2020
Platelet-bound C4d Is Associated with Platelet Activation and Arterial Thrombotic Events
Yevgeniya Gartshteyn¹, Adam Mor², Daichi Shimbo², Leila Khalili³, Teja Kapoor⁴, Laura Geraldino-Pardilla⁵, Roberta Vezza Alexander⁶, Thierry Dervieux⁷ and Anca Askanase², ¹Columbia University College of Physicians and Surgeons, Glen Rock, NJ, ²Columbia University College of Physicians and Surgeons, New York, NY, ³Columbia University Medical Center, New Haven, CT, ⁴Columbia University College of Physicians and Surgeons, Leonia, NJ, ⁵Division of Rheumatology, Columbia University Vagelos College of Physicians and Surgeons, New York, ⁶Exagen Inc, Vista, CA, ⁷Prometheus Biosciences Inc, Irvine, CA
Background/Purpose: Platelets have a well-defined role in arterial thrombosis, and platelet-bound complement activation products (PC4d) correlate with vascular thromboses in patients with Systemic Lupus Erythematosus…
Abstract Number: 1669 • ACR Convergence 2020
Genetics of Age at Diagnosis in Systemic Lupus Erythematosus
Raffaella Carlomagno¹, Fangming Liao², JingJing Cao², Dafna Gladman³, Marisa Klein-Gitelman⁴, Andrea Knight⁵, Deborah Levy¹, Karen Onel⁶, Andrew Paterson², Christine Peschken⁷, Janet Pope⁸, Zahi Touma⁹, Murray Urowitz¹⁰, Declan Webber¹, Joan Wither¹¹, Earl D. Silverman¹² and Linda Hiraki¹³, ¹Division of Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ²Genetics & Genome Biology, Research Institute, The Hospital for Sick Children, Toronto, Canada, ³Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, ⁴Division of Rheumatology, Department of Pediatrics, Ann & Robert H. Lurie Children’s Hospital of Chicago, Chicago, IL, ⁵Division of Rheumatology, The Hospital for Sick Children and Department of Paediatrics, University of Toronto, Toronto, ON, Canada, ⁶Pediatric Rheumatology, Hospital for Special Surgery, New York, NY, ⁷Departments of Medicine and Community Health Sciences, University of Manitoba, Winnipeg, MB, Canada, ⁸Department of Medicine, University of Western Ontario, St. Joseph's Health Centre, London, ON, Canada, ⁹University of Toronto, Toronto, ON, Canada, ¹⁰University Health Network, University of Toronto, Toronto, ON, Canada, ¹¹University of Toronto Lupus Clinic, Centre for Prognosis Studies in Rheumatic Diseases, Toronto Western Hospital, University Health Network, Toronto, ON, Canada, ¹²Division of Rheumatology, The Hospital for Sick Children, Translational Medicine, Research Institute, The Hospital for Sick Children, and Department of Paediatrics, University of Toronto., Toronto, ON, Canada, ¹³Division of Rheumatology, The Hospital for Sick Children, Child Health Evaluative Sciences, Research Institute, The Hospital for Sick Children, and Department of Paediatrics, University of Toronto., Toronto, ON, Canada
Background/Purpose: Genome wide association studies (GWAS) have identified >90 SNPs associated with systemic lupus erythematosus (SLE) risk. However, there may be additional loci impacting the…
Abstract Number: 1768 • ACR Convergence 2020
The Importance of Pregnancy Planning in Lupus Pregnancies
Aardra Rajendran¹, Amanda Eudy², Stephen Balevic³ and Megan Clowse⁴, ¹Duke University, Lewisville, NC, ²Duke University, Durham, NC, ³Duke University, Hillsborough, NC, ⁴Duke University, Chapel Hill, NC
Background/Purpose: Given the clinical importance of the pre-conception period in lupus pregnancy management and because pregnancy planning can be potentially improved, this study explores the…
Abstract Number: 1798 • ACR Convergence 2020
IgE Anti-dsDNA Antibodies in Systemic Lupus Erythematosus Are Associated with Higher Disease Activity at the Baseline and in Longterm Follow-up
Omer Pamuk¹, Zerai Manna², Rutha Adhanom², Xiaobai Li³, Mariana Kaplan⁴ and Sarfaraz Hasni², ¹Rheumatology Fellowship and Training Branch, NIAMS/NIH, Bethesda, MD, ²Lupus Clinical Trials Unit, NIAMS/NIH, Bethesda, MD, ³Biostatistics and Clinical Epidemiology Service, Clinical Center, NIH, Bethesda, MD, ⁴National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, MD
Background/Purpose: Recent reports indicate that autoreactive anti-dsDNA IgE autoantibodies and IgE immune complexes and can activate innate and adaptive immunity leading to amplification of lupus…
Abstract Number: 1816 • ACR Convergence 2020
Urine Biomarkers of Tubulointersitital Damage in Lupus Nephritis
Brianna Lally¹, Shudan Wang², Sammy Chalmers³, Wenzhu Mowrey³, Tamar Rubinstein⁴, Beatrice Goilav⁵ and Anna Broder⁶, ¹Albert Einstein College of Medicine, Bronx, NY, ²Albert Einstein College of Medicine, New York, NY, ³Albert Einstein College of Medicine, Bronx, ⁴Albert Einstein College of Medicine / Montefiore Medical Center, White Plains, NY, ⁵The Children’s Hospital at Montefiore, Albert Einstein College of Medicine, Bronx, NY, ⁶Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY
Background/Purpose: Tubulointerstitial disease (TID), defined as tubulointerstitial inflammation (TII) or interstitial fibrosis/tubular atrophy (IFTA), is associated with progression to end stage renal disease (ESRD) in…
Abstract Number: 1832 • ACR Convergence 2020
Barriers to Medication Adherence and Degree of Nonadherence in a Systemic Lupus Erythematosus Outpatient Population
Courtney Hardy¹, Dafna Gladman², Jiandong Su³, Nathalie Rozenbojm⁴ and Murray Urowitz⁵, ¹University of Toronto, Toronto, ON, Canada, ²Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, ³University of Toronto Lupus Clinic, Centre for Prognosis Studies in Rheumatic Diseases, Toronto Western Hospital, University Health Network, Toronto, ON, Canada, ⁴University Health Network, Toronto, ON, Canada, ⁵University Health Network, University of Toronto, Toronto, ON, Canada
Background/Purpose: It has been reported that 50% to 75% of patients with SLE do not adhere to their medications. However, the reasons for nonadherence are not clear.…
Abstract Number: 1980 • ACR Convergence 2020
Understanding the Relationship Between Illness Perceptions and Self-Efficacy Among Latin Americans with SLE Through the Hablemos De Lupus Facebook Page
Erica Crosley¹, Claudia Elera-Fitzcarrald², Leandro Gabriel Ferreyra Garrot³, Yurilis Fuentes-Silva⁴, Soledad Ibañez⁵, Bernardo Pons-Estel⁶, Cristina Reátegui-Sokolova⁷ and Cristina Drenkard⁸, ¹The Johns Hopkins University School of Medicine, Baltimore, MD, ²Department of Rheumatology. Hospital Nacional Guillermo Almenara Irigoyen. EsSalud; Universidad Científica del Sur, Lima, Peru, ³Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ⁴Universidad de Oriente, Ciudad Bolívar, Venezuela, ⁵Sanatorio Güemes, Buenos Aires, Argentina, ⁶Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Rosario, Santa Fe, Argentina, ⁷Hospital Guillermo Almenara Irigoyen; Universidad San Ignacio de Loyola, Lima, Peru, ⁸Division of Rheumatology, Department of Medicine, Emory School of Medicine, Atlanta, GA
Background/Purpose: SLE disproportionately strikes Latinos, who are also at high risk for poor outcomes. Self-efficacy (SE) to manage chronic disease correlates with outcomes through self-management…
Abstract Number: 0002 • ACR Convergence 2020
Hydroxychloroquine and Chloroquine and Hospitalizations for Viral Infection in the Pre-COVID-19 Era
Cristiano Moura¹, Marina Machado¹, Celline Almeida-Brasil¹, Jeffrey R Curtis², Kevin Winthrop³, Michal Abrahamowicz¹ and Sasha Bernatsky⁴, ¹McGill University, Montreal, Canada, ²Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ³Oregon Health & Science University, Portland, OR, ⁴The Research Institute of the McGill University Health Centre, Montreal, ON, Canada
Background/Purpose: Chloroquine (CQ) and hydroxychloroquine (HCQ) have been shown to have antiviral properties and were considered as potential therapeutic options amid the COVID-19 pandemic. The…
Abstract Number: 0252 • ACR Convergence 2020
Corticosteroid and Opioid Use Remain High in Systemic Lupus Erythematosus Patients Receiving Biologic Therapy: A Retrospective Claims Database Analysis
Julie Birt¹, Jianmin Wu¹, Kirstin Griffing¹, Natalia Bello², Nicole Princic³, Isabelle Winer³, Carolyn Lew³ and Karen Costenbader⁴, ¹Eli Lilly and Company, Indianapolis, IN, ²Eli Lilly and Company, Indianapolis, ³IBM Watson Health, Cambridge, MA, ⁴Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: SLE is managed by variable combinations of five drug classes: antimalarials, biologics, corticosteroids, non-steroidal anti-inflammatory agents, and immunosuppressants. Opioids are commonly prescribed to SLE…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].